Successful fresh formulation CD19 CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia. A Case Report
The favorable clinical response observed in our patient, along with other reports demonstrating preliminary efficacy and limited toxicity, supports further study of CD19 CAR-T cell therapy in GAD65 neurological disorders.
Authors
- Mantas Vaišvilas (ORCID: https://orcid.org/0000-0002-9306-610X)
- David Petrosian (ORCID: https://orcid.org/0009-0008-8075-9514)
- Skirmante Cernauskiene
- Laimonas Griškevičius (ORCID: https://orcid.org/0000-0002-3731-1537)
- Nataša Giedraitienė (ORCID: https://orcid.org/0000-0003-2111-363X)
- Mindaugas Stoskus
Institutions
- Vilnius University (LT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.3389/fimmu.2026.1755797
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00